openPR Logo
Press release

GLP-1 Receptor Agonist Market worth $9.38 billion by 2030, growing at a CAGR of 11.19% - Exclusive Report by 360iResearch

11-04-2023 01:35 PM CET | Health & Medicine

Press release from: 360iResearch

GLP-1 Receptor Agonist Market | 360iResearch

GLP-1 Receptor Agonist Market | 360iResearch

The "GLP-1 Receptor Agonist Market by Product (Bydureon, Ozempic, Saxenda), Drug Class (Albiglutide, Dulaglutide, Exenatide), Route of Administration, Distribution Channel, Application - Global Forecast 2023-2030" report has been added to 360iResearch.com's offering.

The Global GLP-1 Receptor Agonist Market to grow from USD 4.01 billion in 2022 to USD 9.38 billion by 2030, at a CAGR of 11.19%.

Request a Free Sample Report @ https://www.360iresearch.com/library/intelligence/glp-1-receptor-agonist?utm_source=openpr&utm_medium=referral&utm_campaign=sample

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the GLP-1 Receptor Agonist Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in the GLP-1 Receptor Agonist Market. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

Key Company Profiles:

The report delves into recent significant developments in the GLP-1 Receptor Agonist Market, highlighting leading vendors and their innovative profiles. These include 9 Meters Biopharma, Inc., A-S Medication Solutions, LLC, Amgen Inc., AstraZeneca PLC, Biora Therapeutics, Inc., Eli Lilly and Company, Hanmi Pharm.Co., Ltd., Innovent Biologics (Suzhou) Ltd., Jiangsu Hengrui Medicine Co., Ltd., Merck KGaA, Novo Nordisk A/S, Optum, Inc., Paige Biomedicine (Suzhou) Co., Ltd., Pfizer Inc., and Sun Pharmaceutical Industries Limited.

Inquire Before Buying @ https://www.360iresearch.com/library/intelligence/glp-1-receptor-agonist?utm_source=openpr&utm_medium=referral&utm_campaign=inquire

Market Segmentation & Coverage:

This research report categorizes the GLP-1 Receptor Agonist Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Product, market is studied across Bydureon, Ozempic, Saxenda, Trulicity, and Victoza. The Victoza is projected to witness significant market share during forecast period.

Based on Drug Class, market is studied across Albiglutide, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide. The Albiglutide is projected to witness significant market share during forecast period.

Based on Route of Administration, market is studied across Oral and Parenteral. The Oral is projected to witness significant market share during forecast period.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Retail Pharmacies is projected to witness significant market share during forecast period.

Based on Application, market is studied across Liver Cirrhosis, Non-Alcoholic Steatohepatitis, Obesity, and Type 2 Diabetes Mellitus. The Obesity is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Key Topics Covered:

1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
6. GLP-1 Receptor Agonist Market, by Product
7. GLP-1 Receptor Agonist Market, by Drug Class
8. GLP-1 Receptor Agonist Market, by Route of Administration
9. GLP-1 Receptor Agonist Market, by Distribution Channel
10. GLP-1 Receptor Agonist Market, by Application
11. Americas GLP-1 Receptor Agonist Market
12. Asia-Pacific GLP-1 Receptor Agonist Market
13. Europe, Middle East & Africa GLP-1 Receptor Agonist Market
14. Competitive Landscape
15. Competitive Portfolio
16. Appendix

The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:
1. What is the market size and forecast of the GLP-1 Receptor Agonist Market?
2. Which are the products/segments/applications/areas to invest in over the forecast period in the GLP-1 Receptor Agonist Market?
3. What is the competitive strategic window for opportunities in the GLP-1 Receptor Agonist Market?
4. What are the technology trends and regulatory frameworks in the GLP-1 Receptor Agonist Market?
5. What is the market share of the leading vendors in the GLP-1 Receptor Agonist Market?
6. What modes and strategic moves are considered suitable for entering the GLP-1 Receptor Agonist Market?

Read More @ https://www.360iresearch.com/library/intelligence/glp-1-receptor-agonist?utm_source=openpr&utm_medium=referral&utm_campaign=analyst

Contact 360iResearch

Mr. Ketan Rohom
Sales & Marketing,
Office No. 519, Nyati Empress,
Opposite Phoenix Market City,
Vimannagar, Pune, Maharashtra,
India - 411014.
sales@360iresearch.com
+1-530-264-8485
+91-922-607-7550

About 360iResearch

360iResearch is a market research and business consulting company headquartered in India, with clients and focus markets spanning the globe.

We are a dynamic, nimble company that believes in carving ambitious, purposeful goals and achieving them with the backing of our greatest asset - our people.

Quick on our feet, we have our ear to the ground when it comes to market intelligence and volatility. Our market intelligence is diligent, real-time and tailored to your needs, and arms you with all the insight that empowers strategic decision-making.

Our clientele encompasses about 80% of the Fortune Global 500, and leading consulting and research companies and academic institutions that rely on our expertise in compiling data in niche markets. Our meta-insights are intelligent, impactful and infinite, and translate into actionable data that support your quest for enhanced profitability, tapping into niche markets, and exploring new revenue opportunities.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release GLP-1 Receptor Agonist Market worth $9.38 billion by 2030, growing at a CAGR of 11.19% - Exclusive Report by 360iResearch here

News-ID: 3276039 • Views:

More Releases from 360iResearch

Rising Incidence of Human Metapneumovirus in Vulnerable Populations Boosts Global Treatment Demand
Rising Incidence of Human Metapneumovirus in Vulnerable Populations Boosts Globa …
In recent years, the silent ascent of human metapneumovirus (HMPV) infections has begun to capture significant attention within the realm of infectious diseases. As we advance in medical science, unraveling complexities of age-old pathogens like common influenza or emerging illnesses like COVID-19, a critical discourse has been emerging around HMPV. Particularly, there seems to be a burgeoning acknowledgment of its growing impact on vulnerable global populations, propelling an increased demand
The Meat Alternatives Market size was estimated at USD 9.39 billion in 2023 and expected to reach USD 10.06 billion in 2024, at a CAGR 7.63% to reach USD 15.71 billion by 2030.
The Meat Alternatives Market size was estimated at USD 9.39 billion in 2023 and …
From Appetite to Advocacy: The Rising Demand for Meat Alternatives In recent years, the global food industry has been undergoing a remarkable transformation, driven primarily by an increasing consumer demand for healthier, sustainable, and ethically sourced food products. This seismic shift has brought traditional meat alternatives and high-protein plant-based foods into the spotlight. As the world becomes more conscious of the implications of meat consumption on health and the environment, the
The Mobility-as-a-Service Market size was estimated at USD 264.80 billion in 2023 and expected to reach USD 292.84 billion in 2024, at a CAGR 11.08% to reach USD 552.63 billion by 2030.
The Mobility-as-a-Service Market size was estimated at USD 264.80 billion in 202 …
Unpacking the Surge in Investments and Collaborations to Bolster Mobility-as-a-Service In recent years, as urban landscapes continually evolve, a transformative shift known as Mobility-as-a-Service (MaaS) has reshaped the way we perceive transportation. Marked by the integration of various forms of transport services into a single accessible on-demand mobility solution, MaaS is rapidly gaining traction across global cities. As an emerging paradigm, it's not just shaping the future of travel but also
The Data Center Services Market size was estimated at USD 56.65 billion in 2023 and expected to reach USD 62.23 billion in 2024, at a CAGR 9.99% to reach USD 110.34 billion by 2030.
The Data Center Services Market size was estimated at USD 56.65 billion in 2023 …
Smart City Revolutions: Why Data Center Colocation is the Future Backbone In the era of digital transformation, urban landscapes across the globe are undergoing a seismic shift toward becoming "smart cities." The concept of a smart city revolves around using digital technology, IoT (Internet of Things), AI, and data analytics at an unprecedented scale to improve urban infrastructure, manage resources efficiently, and enhance the quality of life for citizens. A vital

All 5 Releases


More Releases for Receptor

Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Market: Competitive Dyna …
Global Info Research offers a latest published report on Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Vitamin D Receptor (VDR or Calcitriol Receptor) Agonist Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in
DP2 Receptor (G Protein-Coupled Receptor 44 Or Chemoattractant Receptor-Homologo …
DP2 Receptor (G Protein-Coupled Receptor 44 Or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist - Pipeline Insight, 2020 report by comprehensive insights of present scenario and growth prospects across DP2 Receptor (G Protein-Coupled Receptor 44 Or Chemoattractant Receptor-Homologous Molecule On Th2 Cells (CRTH2)) Antagonist. A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action,
TRAIL Receptor 1 & Receptor 2 Agonist Pipeline Analysis 2020 Along with Research …
TRAIL Receptor 1 & Receptor 2 Agonist -Pipeline Insight, 2020: The report presents an in-depth assessment of TRAIL Receptor 1 & Receptor 2 Agonist including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for TRAIL Receptor 1 & Receptor 2 Agonist investments from 2020 till 2030 Major Key Players:AbbVie,
Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Recept …
Market Research Hub (MRH) has added a new report titled “Calcitonin Gene Related Peptide Type 1 Receptor, Pharmaceutical Pipeline Research Report” to its vast data repository. Calcitonin Gene Related Peptide Type 1 Receptor (Calcitonin Receptor Like Receptor or CALCRL) pipeline Target constitutes close to 14 molecules. Out of which approximately 14 molecules are developed by Companies. The latest report Calcitonin Gene Related Peptide Type 1 Receptor - Pipeline Review, H1
Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Rece …
"Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H2 2016" The Report covers current Market Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect. Description- Global Markets Directs, Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H2 2016, provides in depth analysis on Transient Receptor Potential Cation
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Recepto …
Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) - Pipeline Review, H2 2016, provides in depth analysis on Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1) targeted pipeline therapeutics. The report provides comprehensive information on the Nociceptin Receptor (Kappa Type 3 Opioid Receptor or KOR3 or Orphanin FQ Receptor or OPRL1), targeted therapeutics, complete with analysis by